February 28, 2013
The unique TMA project will be a two year global project that will involve researchers from around the world collaborating to maximize patient cohorts to produce highly innovative, clinically valuable, and unique TMAs that can facilitate a better understanding of treatment response and resistance and can be utilized to further validate promising prostate cancer tissue-based biomarkers.
The most important component of the project is that samples for the construction of primary human TMAs should consist of tissue samples from patients with both pre and post biochemical recurrence AND/ OR pre and post treatment (either from biopsy or radical prostatectomy tissue). Post-treatment tissue samples could be from either primary local recurrence (post-radiation therapy or post-surgery) or metastasis (soft tissue mass or bone metastasis).